1. A construction method of a transgenic zebrafish model indicating cardiomyocyte autophagy or autophagy flow is characterized by comprising the following steps:

constructing transgenic zebrafish of a specific marker cardiomyocyte autophagosome, wherein the transgenic zebrafish of the specific marker cardiomyocyte autophagosome can co-express EGFP-LC 3;

constructing a transgenic zebra fish of a specific marker cardiomyocyte autophagy flow, wherein the transgenic zebra fish of the specific marker cardiomyocyte autophagy flow can co-express mRFP-EGFP-LC 3.

2. The method for constructing a transgenic zebrafish model indicating cardiomyocyte autophagy or autophagy flow according to claim 1, wherein a tol2 transposon system is used to construct a transgenic zebrafish specifically labeling cardiomyocyte autophagy bodies or a transgenic zebrafish specifically labeling cardiomyocyte autophagy flow.

3. The method for constructing the transgenic zebrafish model indicating cardiomyocyte autophagy or autophagy flow according to claim 1 or 2, wherein a vector co-expressing fluorescent protein EGFP and autophagy-related protein LC3 is constructed, and then the transgenic zebrafish specifically marking cardiomyocyte autophagy bodies is obtained based on the vector.

4. The method for constructing the transgenic zebrafish model indicating cardiomyocyte autophagy or autophagy flow according to claim 1 or 2, wherein a vector co-expressing the fluorescent protein EGFP, the fluorescent protein mRFP and the autophagy-related protein LC3 is constructed, and then the transgenic zebrafish specifically marking cardiomyocyte autophagy flow is obtained based on the vector.

5. The method for constructing the transgenic zebrafish model indicating cardiomyocyte autophagy or autophagy flow according to claim 1 or 2, wherein the zebrafish myl7 promoter is used for expressing the fluorescent protein EGFP and the autophagy-related protein LC3 in the zebrafish cardiomyocytes; or the like, or, alternatively,

fluorescent protein EGFP, fluorescent protein mRFP and autophagy-related protein LC3 were expressed in zebrafish cardiomyocytes using the zebrafish myl7 promoter.

6. The method for constructing the transgenic zebrafish model indicating cardiomyocyte autophagy or autophagy flow according to claim 1, wherein the EGFP fusion autophagy-related protein LC3 labels autophagosomes in the transgenic zebrafish specifically labeled with cardiomyocyte autophagosomes;

in transgenic zebrafish specifically labeled with cardiomyocyte autophagy flux, mRFP fusion to EGFP-LC3 labeled autophagosomes and autophagosomes.

7. The application of the transgenic zebrafish model indicating cardiomyocyte autophagy or autophagy flow obtained by the construction method according to claim 1, is characterized in that the transgenic zebrafish model indicating cardiomyocyte autophagy or autophagy flow is applied to autophagy-related heart disease mechanism research, drug testing or therapeutic method screening.

8. The use of claim 7, wherein the transgenic zebrafish model indicating cardiomyocyte autophagy or autophagy flow is used for in vivo detection of the level of myocardial autophagy and autophagy flow in zebrafish, and comprises the following steps:

(1) constructing transgenic zebrafish specifically marking the autophagosome of the cardiac muscle cell and constructing transgenic zebrafish specifically marking the autophagy flux of the cardiac muscle cell,

(2) zebra fish juvenile fish drug treatment and imaging statistical analysis after cardiac arrest

Treating transgenic zebrafish specifically labeled with cardiomyocyte autophagosomes or transgenic zebrafish juvenile fish specifically labeled with cardiomyocyte autophagy flow with different drugs;

and (3) performing fine fluorescence imaging after the heart is subjected to the arrest treatment, and performing statistical analysis on the autophagy level or autophagy flow condition of the myocardial cells according to the fluorescence imaging result.

9. The use of claim 8, wherein laser channels of EGFP and mRFP are used for single or multilayer imaging of cardiac tissue; respectively counting the number and the density of autophagosomes by using an imaging picture; or to count the ratio of autophagosomes to autophagosomes.

10. The use according to claim 8, characterized in that autophagy flux progression is analyzed by counting the signals coexpressed by mRFP, EGFP indicative of the number and density of autophagosomes, whereas only mRFP positive signals are indicative of the number and density of autophagosomes, and comparing the ratio of autophagosomes and autophagosomes.

Background

Autophagy is an important pathway for regulating cell homeostasis, and a plurality of studies indicate that autophagy of cardiomyocytes plays an important role in cardiac development, the occurrence of heart diseases and treatment. Relevant studies indicate that regulating myocardial autophagy and thereby reducing myocardial apoptosis is one of the important ways to alleviate various heart diseases.

Autophagy is a process of phagocytizing autophagic proteins or organelles and encapsulating them into vesicles (autophagosomes), fusing with lysosomes to form autophagosomes, degrading the encapsulated contents, to achieve cellular homeostasis and organelle turnover. Cells can provide energy and nutrients by degrading non-essential components of the cells themselves through the autophagy pathway, and can also degrade some toxic components to prevent cell damage and apoptosis. The current autophagy assay is mainly to detect autophagosomes of membranous structures and to detect the autophagy marker LC3, and it is more common to detect the autophagy marker LC3 to indicate the level of autophagy due to the convenience of LC3 assays. The level of autophagy development can be analyzed by fluorescent protein fusion LC3 by counting the number and density of autophagosomes via fluorescent signal foci.

In the past, the autophagy level of myocardial cells in animal models is detected by killing animals to obtain heart tissues, biochemically slicing the heart tissues or dyeing specific molecules, so that more experimental links and periods are often needed, the cost is higher, the dynamic process of autophagy regulation cannot be detected, and the effect of various drugs or different molecular approaches in regulating myocardial cell autophagy cannot be detected quickly and massively.

Chinese patent CN 112322661A discloses a method for accurately and quantitatively detecting autophagy flow, which comprises the following steps: (1) constructing an EGFP/LC3HIBIT co-expression vector, wherein the EGFP and the LC3HIBIT are respectively used for independent promoters and do not influence each other; (2) obtaining cells co-expressed by EGFP and LC3-HIBIT protein by a transient transformation or screening monoclonal method; (3) after screening monoclonal stable cells, various genetic operations related to autophagy, screening autophagy-related drugs and the like can be carried out on the basis of the cells; (4) and setting a program on the multifunctional microplate reader to respectively determine luminescence and fluorescence reading values, and calibrating HIBIT reading values caused by cell differences by taking EGFP as an internal reference in the experiment, thereby accurately reflecting the autophagy degree of cells. However, the technical scheme of the patent is non-living body detection and has large application limitation.

Disclosure of Invention

The invention aims to overcome the defects in the prior art and provide a construction method and application of a transgenic zebra fish model which can rapidly detect the effect of various drugs or different molecular pathways in the regulation of myocardial cell autophagy and indicates myocardial cell autophagy or autophagy flow.

The purpose of the invention can be realized by the following technical scheme:

the method for constructing the transgenic zebra fish model indicating the autophagy or autophagy flow of the cardiac muscle cells comprises the following steps:

constructing transgenic zebrafish of a specific marker cardiomyocyte autophagosome, wherein the transgenic zebrafish of the specific marker cardiomyocyte autophagosome can co-express EGFP-LC 3;

constructing a transgenic zebra fish of a specific marker cardiomyocyte autophagy flow, wherein the transgenic zebra fish of the specific marker cardiomyocyte autophagy flow can co-express mRFP-EGFP-LC 3.

Further, a transgenic zebrafish specifically marking the autophagic corpuscles of the cardiomyocytes or a transgenic zebrafish specifically marking the autophagic flux of the cardiomyocytes was constructed using the tol2 transposon system.

Further, a vector co-expressing the fluorescent protein EGFP and the autophagy-related protein LC3 is constructed, and then the transgenic zebrafish specifically marking the autophagosome of the cardiac muscle cell is obtained based on the vector.

Further, a vector co-expressing the fluorescent protein EGFP, the fluorescent protein mRFP and the autophagy-related protein LC3 is constructed, and then the transgenic zebra fish specifically marking the autophagy flow of the cardiac muscle cells is obtained based on the vector.

Further, the fluorescent protein EGFP and autophagy-related protein LC3 are expressed in the myocardial cells of the zebra fish by using a zebra fish myl7 promoter; or the like, or, alternatively,

fluorescent protein EGFP, fluorescent protein mRFP and autophagy-related protein LC3 were expressed in zebrafish cardiomyocytes using the zebrafish myl7 promoter.

Further, in transgenic zebrafish specifically labeling cardiomyocyte autophagosome, EGFP fusion autophagy-related protein LC3 labels autophagosome;

in transgenic zebrafish specifically labeled with cardiomyocyte autophagy flux, mRFP fusion to EGFP-LC3 labeled autophagosomes and autophagosomes.

The invention also provides application of the transgenic zebra fish model indicating myocardial cell autophagy or autophagy flow obtained based on the construction method, and the application of the transgenic zebra fish model indicating myocardial cell autophagy or autophagy flow in the study of heart disease mechanisms related to autophagy, drug test or screening of treatment methods.

Further, the transgenic zebra fish model indicating myocardial autophagy or autophagy flow is used for in vivo detection of the myocardial autophagy level and autophagy flow condition of zebra fish, and the method comprises the following steps:

(1) constructing transgenic zebrafish specifically marking the autophagosome of the cardiac muscle cell and constructing transgenic zebrafish specifically marking the autophagy flux of the cardiac muscle cell,

(2) zebra fish juvenile fish drug treatment and imaging statistical analysis after cardiac arrest

Treating transgenic zebrafish specifically labeled with cardiomyocyte autophagosomes or transgenic zebrafish juvenile fish specifically labeled with cardiomyocyte autophagy flow with different drugs;

and (3) performing fine fluorescence imaging after the heart is subjected to the arrest treatment, and performing statistical analysis on the autophagy level or autophagy flow condition of the myocardial cells according to the fluorescence imaging result.

Further, single or multi-layer imaging of cardiac tissue using laser channels of EGFP and mRFP; respectively counting the number and the density of autophagosomes by using an imaging picture; or to count the ratio of autophagosomes to autophagosomes.

Further, autophagy flux progression was analyzed by counting signals coexpressed by mRFP, EGFP indicative of the number and density of autophagosomes, while signals positive only for mRFP were indicative of the number and density of autophagosomes, and comparing the ratio of autophagosomes to autophagosomes.

The invention also provides a method for detecting the autophagy level and autophagy flux of the myocardial cells of the zebra fish in vivo, which comprises the following steps:

(1) transgenic zebrafish specifically labeling cardiomyocyte autophagosomes, or transgenic zebrafish specifically labeling cardiomyocyte autophagy flow:

constructing a zebra fish transgenic line by using a tol2 transposon system; the zebra fish myl7 promoter is used for expressing genes in myocardial cells specifically; EGFP fusion autophagy-related protein LC3 labeled autophagosomes; mRFP fusion EGFP-LC3 labeled autophagosomes and autophagosomes;

(2) drug treatment and cardiac arrest of zebra fish juvenile fish

Treating zebrafish juvenile fish with different drugs and inhibiting pigmentation with PTU; before imaging, fixing juvenile fish by using 4% PFA or immediately imaging by using a 20-time, 40-time or 60-time objective lens after BDM stops beating the heart;

(3) zebra fish myocardial cell autophagy living body imaging

Single or multi-layer imaging of cardiac tissue using laser channels of EGFP and mRFP;

(4) image analysis for counting autophagy level or autophagy flow of myocardial cells

Respectively counting the number and the density of autophagosomes by using an imaging picture; or to count the ratio of autophagosomes to autophagosomes.

The specific method for constructing the zebra fish transgenic line by using the tol2 transposon system in the step (1) comprises the following steps: when constructing transgenic plasmid, the 5 'element and the 3' element of tol2 are respectively added on two sides of a segment to be transferred into the genome of zebra fish, simultaneously mRNA of transposase is synthesized in vitro, the transgenic plasmid and the mRNA of transposase are simultaneously introduced into fertilized eggs of the zebra fish by microinjection, each 25pg of the transgenic plasmid and the mRNA of the transposase are cultured to be adult, and transgenic offspring is screened by a fluorescent signal and a PCR method after outcrossing.

The step (2) of treating the zebra fish juvenile fish with different medicaments means that the medicaments to be tested have different effective concentrations according to actual treatment effects, and the general range of the concentration of the medicaments tested at present is 1 mu M to 100mM, so that the zebra fish juvenile fish is soaked. The zebra fish juvenile fish is 2-7 days old zebra fish;

the PTU is used for inhibiting the pigment formation, in order to prevent the zebra fish pigment cells from influencing the imaging of the myocardial autophagy, the PTU (with the final concentration of 0.003%) is added within 22-24 hours of the fertilization of the zebra fish embryos to inhibit the generation of the pigment cells, and the liquid is changed every day until the imaging experiment.

The invention also provides application of the method for detecting the autophagy level and autophagy flow condition of the myocardial cells of the zebra fish in the mechanism research, the drug detection and the treatment of the heart diseases related to autophagy.

The fluorescent protein EGFP has acid sensitivity, the fluorescence intensity of the EGFP is obviously reduced under acidic conditions, and the fluorescent protein mRFP has low sensitivity to acid. During autophagy, after an autophagososome is combined with a lysosome to form an autophagososome, the acidic environment of the autophagososome is obviously enhanced, so that the strength of EGFP in the autophagososome is obviously reduced, and the mRFP is not greatly changed. Therefore, autophagy flux progression can be analyzed by counting the signals coexpressed by mRFP, EGFP after fusion with LC3, while the signals positive for mRFP alone indicate the number and density of autophagosomes, and the ratio of autophagosomes and autophagosomes can be compared. Under the physiological state, the heart of the zebra fish continuously beats, the heart can be subjected to heartbeat stopping treatment (heartbeat can be recovered at the later stage) to carry out fine fluorescence imaging, and the autophagy level or autophagy flow condition of the myocardial cells can be statistically analyzed according to the fluorescence imaging result.

The zebra fish juvenile fish model has the advantages of in vitro fertilization, small individual volume and transparent imaging, is very convenient for in vivo observation and imaging, and has very simple operation of drug treatment, so that the establishment of the zebra fish model capable of in vivo detection of the myocardial cell autophagy level has great significance for research and drug test screening in the field.

The invention is based on the establishment of a small animal model of a living body to rapidly detect the autophagy level or autophagy flow condition of the cardiac muscle cells, and can be used for researching the mechanism of the cardiac disease related to the autophagy of the cardiac muscle cells and testing the medicine and the treatment method.

The invention constructs a transgenic zebra fish model for in vivo detection of myocardial cell autophagy and autophagy flow, and establishes a detection method for myocardial cell autophagy level and autophagy flow change after related drug treatment. The method not only can rapidly detect the effect of various drugs on the regulation of the autophagy of the myocardial cells, but also can be used for screening drugs related to the autophagy of the myocardial cells, the effect of the autophagy on various diseases of the heart, the mechanism research of different molecular pathways in the autophagy regulation of the myocardial cells and the like.

Compared with the prior art, the invention has the following beneficial effects:

1) the invention establishes a transgenic zebra fish model for detecting the autophagy level or autophagy flow of cardiac muscle cells in vivo. By specifically expressing the fluorescent protein fused autophagy marker LC3 in the zebra fish myocardial cells, the autophagy-related drug test shows that the model can well indicate the autophagy level of the myocardial cells.

2) Reliability: repeated experiments and different drug tests show that detecting myocardial autophagy in zebra fish can stably indicate the regulation and control of myocardial autophagy by different drugs.

3) The popularization prospect is as follows: at present, no relevant report of a model for rapidly detecting myocardial cell autophagy or autophagy flow of a zebra fish model and a corresponding method exists. Therefore, the method developed by the present invention is crucial for the study of autophagy-related heart diseases and for the screening and testing of drugs and therapeutic methods that can modulate autophagy of cardiomyocytes.

Drawings

FIG. 1 is the establishment and verification of zebra fish line for detecting myocardial autophagy; wherein: a) a schematic diagram of a transgenic plasmid structure; b) the transgenic line shows that the heart of the zebra fish expresses EGFP; c) identifying the genotype by PCR; d) example 1 confocal microscopy images of zebra fish heart bright field; e) imaging results of heart sites of young fish of CQ group and control group using confocal laser microscopy in example 1;

FIG. 2 is the establishment and verification of a zebra fish product line for detecting cardiomyocyte autophagosomes and autophagosomes; wherein a) schematic representation of the transgene plasmid structure; b) identifying the genotype by PCR; c) in example 2, confocal microscopy was used to image brightfield images of the heart; wherein d is a control group, and e is a drug adding induction group;

FIG. 3 is a confocal microscope image of the zebrafish heart 24 hours after treatment with different drugs in example 3;

FIG. 4 is a graph of the detection of cardiomyocyte autophagosome flow in the zebrafish MIRI model of example 4;

a) the zebra fish heart confocal microscope imaging images of the MIRI group and the control group; b) images were counted for density data of autophagosomes and autophagosomes.

Detailed Description

The invention is described in detail below with reference to the figures and specific embodiments.

Example 1

The establishment and verification of the zebra fish line for detecting myocardial autophagy are described in figure 1, and the specific method comprises the following steps:

(1) transgenic zebrafish specifically labeling cardiomyocyte autophagosomes:

constructing a zebra fish transgenic line by using a tol2 transposon system, wherein the zebra fish myl7 promoter is cloned from a zebra fish genome to specifically express genes in cardiac muscle cells; cloning LC3 autophagy-related protein from zebrafish cDNA template, and fusing EGFP to the N-terminal of LC3 by PCR fusion to mark autophagosomes; connecting myl7 promoter and EGFP-LC3 in sequence to a vector containing tol2 element to construct a transgenic plasmid (for example, a structural schematic diagram of the transgenic plasmid is shown in figure 1a, and a transgenic line shown in figure 1b shows that zebrafish heart expresses EGFP); extracting the constructed plasmid, mixing the plasmid with transposase mRNA, and injecting 25pg of the plasmid and the transposase mRNA into fertilized eggs of the zebra fish; breeding the injected zebrafish embryos to adults; carrying out outcrossing with wild zebra fish to obtain offspring zebra fish juvenile fish, and identifying a stable transgenic line 2-3 days after fertilization by fluorescence and PCR (shown in figure 1 c); soaking 2-day-old young fish fertilized with correct transgenic zebra fish in Chloroquine (CQ) at 20 mu M, and fixing with 4% paraformaldehyde for 24 hours to obtain a CQ group; taking the group without drug as the control group, and immediately imaging the heart of the young fish of the CQ group and the control group by using a confocal microscope to confirm whether the strain can display autophagosome, as shown in FIG. 1d, it can be seen that the bright field imaging in the present example shows that the whole development and the heart development of the transgenic strain are normal;

(2) drug treatment and cardiac arrest of zebra fish juvenile fish

Treating zebrafish juvenile fish with different drugs and inhibiting pigmentation with PTU; before imaging, fixing juvenile fish by using 4% PFA or immediately imaging by using a 20-time, 40-time or 60-time objective lens after BDM stops beating the heart;

treating the zebra fish juvenile fish with different medicaments (the specific concentration of the different medicaments is based on actual conditions, and the overall form which does not influence the development of the zebra fish juvenile fish is taken as a standard), and soaking the zebra fish juvenile fish; wherein, CQ group represents juvenile fish soaked with Chloroquine (CQ)20 μ M, and control group represents no-drug group. The zebra fish juvenile fish is 2-7 days old zebra fish;

inhibition of pigmentation using PTU means that zebrafish embryos are treated with PTU (final concentration of 0.003%) within 22-24 hours after fertilization, and are changed to imaging points once a day.

(3) Zebra fish myocardial cell autophagy living body imaging

Single or multi-layer imaging of CQ and control groups of juvenile fish heart tissue using the laser channel of EGFP; the heart of the zebra fish juvenile fish to be imaged is imaged by a laser confocal microscope immediately after the heart of the zebra fish juvenile fish to be imaged is stopped, the channel selects laser with 488 nanometers wavelength, the image resolution is set to be 1024X1024 pixel points, and a single-layer or multi-layer imaging can be carried out by selecting 20-time, 40-time or 60-time objective lenses and 1-4 times of a magnified imaging area (ZOOM).

(4) Image analysis statistics of myocardial cell autophagy level

The imaging pictures respectively count the number and density of autophagosomes. The imaging picture is opened by using ImageJ software, the number of the fluorescent dots (shown in figure 1 e) is counted, the whole area of the heart tissue can be simultaneously selected, the area is counted by using the function of the software, and the density of the autophagosomes is obtained by dividing the area by the number of the fluorescent dots. As can be seen from fig. 1e, the number of autophagosomes in cardiomyocytes significantly increased after induction of autophagy (indicated by arrows).

Example 2

The establishment and verification of zebra fish lines for detecting cardiomyocyte autophagosomes and autophagosomes are shown in figure 2, and the specific method is as follows:

(1) specific labeling of transgenic zebrafish of cardiomyocyte autophagy flow:

constructing a zebra fish transgenic line by using a tol2 transposon system, wherein the zebra fish myl7 promoter is cloned from a zebra fish genome to specifically express genes in cardiac muscle cells; cloning LC3 autophagy-related protein from zebrafish cDNA template, and fusing mRFP and EGFP to the N-terminal of LC3 in sequence by PCR fusion to mark autophagosome; constructing a transgenic plasmid by sequentially connecting an myl7 promoter and mRFP-EGFP-LC3 into a vector containing a tol2 element (shown in a figure 2 a); extracting the constructed plasmid, mixing the plasmid with transposase mRNA, and injecting the mixture into fertilized eggs of zebra fish by 25pg each; breeding the injected zebrafish embryos to adults; carrying out outcrossing with wild zebra fish to obtain offspring zebra fish juvenile fish, and identifying a stable transgenic line 2-3 days after fertilization by fluorescence and PCR (shown in figure 2 b); after fertilization of a correct transgenic zebrafish, young 2 days old fish are soaked in Chloroquine (CQ) for 20 mu M, fixed by 4% paraformaldehyde after 24 hours, and immediately imaged on the heart by using a confocal microscope to confirm whether the strain can show autophagosomes and autophagosomes, as shown in FIG. 2c, it can be seen that bright field imaging in the embodiment shows that the whole development and the heart development of the transgenic strain are normal;

(2) drug treatment and cardiac arrest of zebra fish juvenile fish

Treating the zebra fish juvenile fish with different medicaments (the specific concentration of the different medicaments is based on actual conditions, and the overall form which does not influence the development of the zebra fish juvenile fish is taken as a standard), and soaking the zebra fish juvenile fish; wherein the CQ group represents that juvenile fish is soaked in Chloroquine (CQ) by 20 mu M, the control group represents that no medicine is added, and the juvenile zebra fish is zebra fish 2-7 days old;

the use of PTU for inhibiting pigmentation means that the zebra fish embryos are added with PTU treatment (the final concentration is 0.003 percent) within 22-24 hours after fertilization, and the liquid is changed once a day until an imaging point;

(3) zebra fish myocardial cell autophagy living body imaging

Single or multi-layer imaging of cardiac tissue using laser channels of EGFP and mRFP; the heart of the zebra fish juvenile fish to be imaged is imaged by a laser confocal microscope immediately after the heart of the zebra fish juvenile fish to be imaged is stopped, lasers with wavelengths of 488 and 595 nanometers are selected in a channel, the image resolution is set to be 1024X1024 pixel points, and a single-layer or multi-layer imaging can be carried out by selecting 20-time, 40-time or 60-time objective lenses and 1-4 times of a ZOOM imaging area (ZOOM).

(4) Image analysis for counting autophagy level and autophagy flow of myocardial cells

Respectively counting the number and the density of autophagosomes by using an imaging picture; or to count the ratio of autophagosomes to autophagosomes.

The imaging pictures were opened using ImageJ software and the number of fluorescent dots (as shown in figures d-e, significant increase in the number of autophagosomes (indicated by grey arrows) and autophagosomes (indicated by white arrows) in cardiomyocytes following induction of autophagy) was counted, including mRFP and EGFP co-localized dots (indicated by grey arrows) and mRFP-labeled dots (indicated by white arrows), and the whole area of the heart tissue could be simultaneously selected, the functional statistical area of the software self-band was used and the density of autophagosomes was obtained by dividing the number of mRFP and EGFP co-localized fluorescent dots by the area and the number of mRFP-labeled dots by the area alone, and the ratio between the density of autophagosomes and the density of autophagosomes was used to count the level of autophagosomal flow.

Example 3

The results of experiments on the modulation of cardiomyocyte autophagy by different drugs are shown in fig. 3.

Drug test method CQ treatment method as in example 1, wherein the control group was the no drug added group, and the musk was dissolved in DMSO to obtain a saturated solution 1: 16000 diluting for use; dissolving atorvastatin calcium into a saturated solution by using DMSO (dimethyl sulfoxide), and diluting the solution at a ratio of 1: 8000; diluting the levocarnitine injection by 1:20 for use; diluting dibutyryl adenosine cyclophosphate calcium injection at a ratio of 1: 200; dissolving trimetazidine hydrochloride into a saturated solution by using water, and diluting the solution at a ratio of 1:500 for use; dissolving metonol tartrate in water to obtain saturated solution, and diluting at a ratio of 1: 2000; dissolving valsartan into a saturated solution by using DMSO, and diluting the solution at a ratio of 1: 8000; the aspirin is dissolved into a saturated solution by DMSO and then diluted 1:4000 for use. These drugs were found to significantly increase the number of cardiomyocytes autophagosomes 24 hours after drug treatment using confocal microscopy (as shown by the fluorescent dots in figure 3).

Example 4

Detecting the autophagy fluid flow condition of the cardiac muscle cells in a zebra fish MIRI model: the young fish 3 days after fertilization were treated with 40. mu.M BDM to arrest their heartbeats, and after 3 hours BDM was eluted to restore their heartbeats to establish a MIRI model group as a MIRI group, while the control group was cultured normally without any other treatment process as a control group. After 24 hours the heart was fixed using 4% PFA and immediately imaged (as in example 2) and the results are shown in figure 4, and the density of autophagosomes and autophagosomes was counted from the pictures and the density of autophagosomes was found to be significantly increased in the MIRI model relative to the control. The density of autophagosomes was further divided by the density of autophagosomes and compared to controls found to significantly reduce the progression of autophagic flow in the MIRI group.

As can be seen from fig. 4, zebrafish cardiomyocytes autophagosomes and autophagosomes were significantly increased in MIRI, but the progression of autophagic flux was significantly decreased.